Phase I dose-escalation study of novel oral multi-target tumor growth inhibitor (MTGI) ZK 304709 administered daily for 7 days of a 21-day cycle to patients with advanced solid tumors

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Author(s): Graham J, Wagner K, Plummer R, Wiedenmann B, Cassidy J, Kowal K, McCoy C, Calvert H

Publication type: Conference Proceedings (inc. Abstract)

Publication status: Published

Conference Name: Journal of Clinical Oncology: 42nd Annual Meeting of the American Society of Clinical Oncology

Year of Conference: 2006

Pages: 97S abstract no. 2073

ISSN: 0732-183X

Publisher: American Society of Clinical Oncology

URL: http://meeting.ascopubs.org/cgi/content/abstract/24/18_suppl/2073

Library holdings: Search Newcastle University Library for this item

ISBN: 15277755

ePrints